Course

Breaking Down Lab Reports in Rheumatoid Arthritis

0 out of 2 steps completed0%
0 Lessons

Breaking Down Lab Reports in Rheumatoid Arthritis

RNP – Volume 3 – Issue 1

Learning Objectives

  1. Define key terms such as specificity, sensitivity, and positive predictive value as they relate to the diagnostic and prognostic value of individual laboratory tests
  2. Explain the utility and limitations of specific laboratory tests commonly ordered in patients with RA
  3. Describe the differences in prognosis between patients with seronegative vs. seropositive disease
  4. Identify future opportunities with laboratory testing that may improve the ability to predict patients’ response to treatment

Disclosure

It is the policy of the Rheumatology Nurses Society (RNS) that the education presented within RNS-provided activities be unbiased and based upon scientific evidence. To help participants make judgments about the presence of bias, RNS provides information that planners, teachers, authors, developers, and activity managers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this educational activity. Relationships that an individual may have with commercial entities have been disclosed and reviewed, and any potential conflicts have been resolved.

Relationships are abbreviated as follows:
E, Educational planning committee;
G, Grant/research support recipient;
A, Advisor/review panel member;
C, Consultant;
S, Stock shareholder;
SB, Speaker bureau;
PE, Promotional event talks;
H, Honoraria;
O, Other

Sheree Carter, PhD, RN has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene, Antares, Amgen/A.

Jacqueline Fritz, RN, MSN, CNS has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: GlaxoSmithKline/A, Celgene, AbbVie/SB.

Elizabeth Kirchner, CNP has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Iroko, Amgen, Sanofi/A, Crescendo Biosciences/SB.

Iris Zink, MSN, NP has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie/A,SB; Celgene, Sanofi/A; Antares/C: Bristol Myers-Squibb/SB.

Target Audience

The intended audience for this activity includes rheumatology nurses, rheumatology advanced practice nurses, and infusion nurses.

Content Direction

Scott Kober, MBA, Principal, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Content Freelancer

Anne Jacobson, MPH, CCMEP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Content Peer Reviewer

This newsletter was peer reviewed by Linda Grinnell-Merrick, MS, NP-BC. Ms. Grinnell-Merrick has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene/A,SB; GlaxoSmithKline, Amgen, Iroko/A.

Production Management

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Product Disclosure

This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.